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a b s t r a c t
Background: Declining incidence and spatial heterogeneity complicated the design of phase 3 Ebola vac-
cine trials during the tail of the 2013–16 Ebola virus disease (EVD) epidemic in West Africa. Mathematical
models can provide forecasts of expected incidence through time and can account for both vaccine effi-
cacy in participants and effectiveness in populations. Determining expected disease incidence was critical
to calculating power and determining trial sample size.
Methods: In real-time, we fitted, forecasted, and simulated a proposed phase 3 cluster-randomized vac-
cine trial for a prime-boost EVD vaccine in three candidate regions in Sierra Leone. The aim was to fore-
cast trial feasibility in these areas through time and guide study design planning.
Results: EVD incidence was highly variable during the epidemic, especially in the declining phase. Delays
in trial start date were expected to greatly reduce the ability to discern an effect, particularly as a trial with
an effective vaccine would cause the epidemic to go extinct more quickly in the vaccine arm. Real-time
updates of the model allowed decision-makers to determine how trial feasibility changed with time.
Conclusions: This analysis was useful for vaccine trial planning because we simulated effectiveness as well
as efficacy, which is possible with a dynamic transmission model. It contributed to decisions on choice of
trial location and feasibility of the trial. Transmission models should be utilised as early as possible in the
design process to provide mechanistic estimates of expected incidence, with which decisions about sam-
ple size, location, timing, and feasibility can be determined.
 2016 Published by Elsevier Ltd.
1. Introduction
West Africa experienced the largest outbreak of Ebola virus
disease (EVD) to date during 2013–16. This epidemic resulted in
more than 25,000 cases and 10,000 deaths. As the epidemic
unfolded in 2014, development of candidate vaccines was acceler-
ated, including evaluation in phase 1–2 studies and phase 3 plan-
ning. However, the rapidly changing incidence both
geographically and in time posed major challenges to the design
and planning of phase 3 trials. Typical study design calculations
do not allow for varying infection rates within and between com-
munities over time, which is especially problematic during the tail
of an epidemic, when few cases occur. Computer simulations
employing empirical statistical models can mitigate some of these
concerns however they require accurate assumptions on incidence,
heterogeneity and, in addition, do not capture the mechanism of an
outbreak. Moreover, an effective vaccine used widely in a given
area (as would be the case in large-scale, population-based vaccine
trials) could in itself further reduce the incidence.
Dynamic models of EVD transmission were developed during
the epidemic to understand the patterns of spread of the virus
and predict the course of the outbreak [1–4]. If these models are
appropriately parameterised and updated, then they can be used
to predict incidence and how it may change in space and time [5].
In addition, dynamic models can account for both the direct and
indirect effect of vaccine-induced immunity and its impact on the
transmission dynamics. That is, they can be used to assess the
extent that the trial itself may affect the transmission dynamics.
Collaboration between the Centre for Mathematical Modelling
of Infectious Disease (CMMID) at the London School of Hygiene &
Tropical Medicine and Janssen Research & Development (Janssen
R&D) was established to rapidly extend a mathematical model of
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EVD [3] to simulate a cluster-randomized phase 3 vaccine trial in
Sierra Leone. The dynamic model and trial simulations were
updated in real-time to match the latest incidence data available.
This collaboration thus enabled a real-time, dynamic assessment
of the feasibility of a potential phase 3 trial, which ultimately
was implemented as a safety and immunogenicity study:
EBOVAC-Salone (NCT02509494). This paper describes how the
model was used to inform the planning of the trial as well as the
decision-making to abandon the effectiveness part of the protocol.
2. Methods
2.1. Collaboration
Collaboration was initiated between CMMID and Janssen R&D
in February 2015. Janssen R&D was seeking a partner to guide
study design and feasibility planning of a phase 3 effectiveness trial
for their heterologous prime-boost vaccine regimen (Ad26.ZEBOV
as prime and MVA-BN-Filo 28 days later as boost), for which
phase 1 trials were on-going.
CMMID had previously developed mathematical models of EVD
transmission to assess the potential for large outbreaks [6], impact
of community care centres on the evolving epidemic [7], and bed
capacity in Sierra Leone [3]. In addition, CMMID members liaised
withWHO on the design and analysis of theWHO EVD vaccine trial
[8].
Collaboration offered a unique opportunity to explore the use of
a dynamic transmission model to evaluate study feasibility. In this
paper, we present the model-based incidence projections and trial
simulations from 15th February 2015, similar to those sent from
LSHTM to the team at Janssen on a weekly basis from February
2015 to May 2015. These were in turn employed by the clinical
study team to evaluate and guide power calculations, study design
as well as trial feasibility. To illustrate the impact of the evolving
epidemic, an update of the projections and simulations at the
end of April is provided as supplementary materials.
2.2. Vaccine trial design
A large-scale cluster-randomized phase 3 trial was designed to
evaluate the effectiveness of prime-boost vaccine regimen against
laboratory-confirmed EVD in an outbreak setting in Sierra Leone
[9]. Sierra Leone is administratively divided into districts, districts
into chiefdoms, and chiefdoms into sections. A trial cluster would
be a section. With vaccine availability at time of study design of
up to four hundred thousand doses of both prime and boost vac-
cine, approximately 160 clusters of 5000 participants (800,000 in
total) were to be assigned in a 1:1 ratio to immediate vaccination
versus no vaccination (control), whereby vaccination would be
offered to the control group after effectiveness was established.
Initially, feasibility, statistical power, and type I error of the trial
were evaluated using simulations which assumed constant inci-
dence through time [9]. Control incidence assumptions of 3, 5,
10, 20 and 40 EVD cases per arm per month (400,000 person-
months) were evaluated, with allowance for heterogeneity
between clusters based on CMMID projections and simulations.
However, the rapidly changing epidemic dynamics in early 2015
meant that these static predictions were unlikely to capture the
epidemiological picture.
2.3. Transmission model for trial
The transmission model extended a previously published model
for transmission of EVD [3]. It was a stochastic compartmental
model, where the population was divided into classes (Fig. 1): Sus-
ceptible (S), Exposed (E), Infectious not yet notified (I), Infectious
and notified (J) and Removed (R, for recovered and immune, or
dead). The infectious compartment was split in two sub-
compartments I and J in order to account for a delay of (on average)
4.8 days to notification of new cases [4]. The model was extended
to mimic the trial design closely, but modelling cluster-level ran-
domization was not possible because there was insufficient data
available at this spatial scale for fitting. It is often difficult to pre-
dict the tails of epidemics, which are characterized by small, local
outbreaks, and stochastic variation. Instead, we assumed a 1:1 ran-
domization at the district level and treated the clusters as indepen-
dent units.
Susceptible people were assumed to be recruited to the trial
for the length of the accrual time, Tr, by entering either the vac-
cine (VS) or control (C1) arms. An average of 2 weeks after
receiving the prime, vaccinated participants entered the compart-
ment, VP, where they were assumed to have a reduced risk of
infection, rp. On receipt of the boost vaccine, they were assumed
to enter VB, and immediately gain the target vaccine efficacy, rb
(Fig. 1). Control participants were assumed to proceed from C1
to C2 at the same rate as VS to VP to maintain comparability.
Parameters that govern rates of transition are given in Table 1.
To account for external influences on transmission – such as
variation in human behavior and introduction of control mea-
sures – we assumed that the transmission rate could change over
time; the extent and direction of change was estimated during
the model fitting process [3]. Hypothetical vaccine efficacy values
were defined in February 2015 for the power calculation of the
effectiveness trial. These values were conservative estimates, cho-
sen to ensure that the planned trial would have sufficient power
in the event of unpredicted changes in incidence, and to decrease
the risk of the study. These hypothetical assumptions are only
working hypotheses and do not necessarily reflect the potential
effect of this candidate vaccine, and these hypothetical values
need to be assessed in the future.
2.4. Incidence data
The model was fitted to weekly confirmed and probable EVD
incidence data from three districts in Sierra Leone (Kambia, Port
Loko, and Western Area) that had on-going epidemics in February
2015 and were therefore candidate areas for a potential vaccine
trial. Data were drawn from the WHO and Sierra Leone situation
reports and ran from 25th May 2014 until the date of fitting and
forecast [10,11]. We used Bayesian methods to fit the model to
the data, namely particle Markov Chain Monte Carlo, which allows
parameter estimation in a stochastic framework.
2.5. Forecasting
We sampled the reproduction number (Rt) 5000 times at the
last fitted data point, and forecasted the epidemic until extinction
under the assumption that the reproduction number did not
change from that time. We retained only forecasts that went
extinct by 1st January 2016 because all regions showed waning
epidemics, and although persistence for a further year was possi-
ble, it was deemed unlikely (Fig. S2). Sampled reproduction num-
bers therefore usually lie below 1 (Fig. S1). Updated estimates of
the reproduction number distribution made in April 2015 have
very little density above 1, which suggests this was a reasonable
assumption.
The forecasted persistence probability at each point of time t
was defined as the probability that at least one infectious individ-
ual remains in the arm at that time, and was computed empirically
by summing over the N forecast trajectories that went extinct by
1st January 2016:
2 A. Camacho et al. / Vaccine xxx (2016) xxx–xxx
Please cite this article in press as: Camacho A et al. Real-time dynamic modelling for the design of a cluster-randomized phase 3 Ebola vaccine trial in Sierra
Leone. Vaccine (2016), http://dx.doi.org/10.1016/j.vaccine.2016.12.019
PðtÞ ¼ 1
N
XN
i¼1
1fEiðtÞþIiðtÞ>0g
with i the index of the sample from the posterior.
We evaluated the impact of trial start date by comparing the
simulated number of cases in the vaccine or control arms. We used
a one-sided Wilcoxon signed rank test to test for the pairwise dif-
ference in the total number of cases between the vaccine and con-
trol arm. In addition, we assessed the effect of vaccine efficacy on
trial success. The persistence probability is calculated as the pro-
portion of 5000 epidemic simulations that are non-extinct at each
time point.
3. Results
3.1. Model fits and projections
Using data as of 15th February 2015, we fitted the model to
weekly confirmed and probable EVD cases (Fig. 2). At that time,
the epidemic was in the tail phase, which is clear from the rapidly
decreasing persistence probability. Visually, incidence data that
has since been observed show excellent agreement with the fore-
casted epidemics (Fig. 2), where 65%, 59%, and 65% of weekly val-
ues lie within the 50% credible interval (CI) in Kambia, Port Loko,
and Western Area respectively. 92%, 92%, and 94% of points lie
within the 95% CI.
Short-term model projections were contrasted with the static
model assumptions from the power analysis of [9] (Fig. 2). In [9]
the control incidence of 5 per 400,000 person-months was identi-
fied as a threshold of sufficient statistical power to initiate the trial.
The model indicates that the incidence could drop below this
threshold between June and August for all three districts, though
the estimates are subject to great uncertainty as can be seen from
the wide 95% credible intervals. Already in April-May, the inci-
dence was possibly too low to initiate the trial.
We now describe the results of the vaccine trial simulations.
The baseline scenario presented in this paper, unless otherwise
specified, is that the trial began on 1st May 2015 using a conserva-
tive working hypothesis of 50% reduction in susceptibility follow-
ing prime vaccine, rising to hypothetical 80% after the boost
vaccine. The populations of Kambia (population 340,000) and Port
Loko (population 558,000) were smaller than the target of 400,000
participants in each arm, so we show simulations for those districts
with each arm of the trial encompassing both – 170,000 in Kambia,
and 230,000 in Port Loko. Western Area had a large enough popu-
lation that the trial could be conducted solely in that district.
3.2. Effect of the start date of the trial
For forecasts made on 15th February 2015 with trial start dates
on 1st May, 1st June and 1st July 2015, there were fewer cases in
both arms when the start date was later (Fig. 3), due to the contin-
ued decline of the epidemic. The later the start date, the lower the
probability that the epidemic was still on-going by the start of the
trial. Although the trial begins on the first of each month, delays
involved in the recruitment of participants, onset of protective
immunity, and time to boost vaccinationmean that cases occurring
in the population are not necessarily trial endpoints, and therefore
do not accrue in the cumulative cases shown in Fig. 3. While the
difference between vaccine and control arms could have been large
by December 2015, the probability of the epidemic persisting until
December was very low. We found the overall number of cases was
larger if the trial was in Kambia and Port Loko combined, compared
to Western Area solely.
The occurrence of a vaccine trial in a candidate region would
affect the persistence probability of the epidemic in that region if
the vaccine were efficacious. In a declining epidemic, this would
cause the epidemic to go extinct faster, reducing the persistence
Fig. 1. Model diagram. Susceptible people were recruited to the trial by entering
either the vaccine (VS) or control (C1) arms. Two weeks after receiving the prime,
vaccinated participants developed protective immunity (rp), and entered the
compartment VP. On receipt of the boost vaccine, they enter VB, and immediately
gain the target vaccine efficacy (rb). Control participants proceed from C1 to C2 at
the same rate as VS to VP to maintain comparability. Transitions have Erlang-
distributed waiting periods with shape equal to 2, apart from S to E, I to J, and J to R,
which are exponentially distributed as well as S to VS or C1, which are step-wise
processes.
Table 1
Parameters used in the model. Most values are fixed based on literature values, while
transmission rate is estimated.
Parameter Description Value Reference
bt Time varying effective contact
rate
Estimated Estimated
kt Time varying force of
infection
bt ðIrþJr Þ
Nr
; r 2 ðV ;CÞ [1]
1/ Average latent period 9.4 days [1]
1/m1 Average infectious period
before notification
4.8 days [1]
1/m2 Average infectious period
after notification
6.4 days [1]
Rt Time-varying reproduction
number
bt ⁄ (1/m1 + 1/v2) –
Nr Total number of subjects
recruited in each arm
170,000 (Kambia)
230,000 (Port
Loko)
400,000 (Western
Area)
Fixed
–
–
Tr Accrual time 12 weeks Fixed
rt Linear recruitment rate in
each arm
Nr/Tr –
1/jp Average time between prime
vaccination and onset of
protection
14 days Fixed
1/jp + 1/
jb
Average time between prime
and boost vaccination
28 days Fixed
1/c Average duration of vaccine
protection
11 months Fixed
rp Hypothetical vaccine efficacy
for prime vaccine
50% Fixed
rb Hypothetical vaccine efficacy
for prime + boost
60%, 80%, 90% Fixed
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probability. This can be seen from Fig. 3, as starting the trial earlier
increased the probability of earlier elimination in the vaccine arms.
Starting the trial later would result in a reduced probability of
detecting a difference in the number of cases between the two
arms and an increased probability of having no cases in either
arm (Fig. 4). In some simulations more cases would be observed
in the control group in comparison to the vaccinated group (a
‘‘negative” effect). Fig. 4 indicates that over 5000 replicates of the
trial, the distribution of the total number of cases is always signif-
icantly different between the vaccine and control arms at all start-
ing time (p < 0.05, Wilcoxon signed rank test). However, when
considering the proportion of trials with a positive or negative
effect (i.e. below or above the diagonal in Fig 4), these proportions
decrease and become more similar as the trial start later, with the
proportion of trials with no cases increasing in the same time.
While a split in favour of the vaccinated group would be expected
under the assumed prime/boost effect, the simulations indicate
that for a trial starting on 1st May, a negative (versus positive)
effect would be observed in respectively 18% vs. 55%, 12% vs. 32%
and 11% vs. 38% of simulations in Kambia, Port Loko and Western
Area. For a trial starting 1st July 2015 the difference became smal-
ler with 13% vs 15%, 4% vs 5% and 3% vs 4% of simulations for the
three districts, respectively. The probability of observing no cases
in either arm increased when the trial started later due to increas-
ing stochastic extinctions (supplementary information).
3.3. Effect of vaccine efficacy
In simulations of this large trial, which is started in the declin-
ing phase of the epidemic, any effective vaccine causes a decrease
in persistence probability of the epidemic (Fig. 5). Higher hypo-
thetical vaccine efficacy leads to quicker extinction of the epi-
demic, although the differences are very small. The simulations
gave very comparable expected number of cases in the vaccine
arm between the hypothetical vaccine efficacy values of 60%, 80%
and 90%, which is shown by the grey, red, and yellow boxplots
(Fig. 5). This finding was consistent for Kambia, Port Loko andWes-
tern Area.
3.4. Real-time updates
The epidemic progressed from February to May 2015, and we
updated the model fits and projections in real time. Here we dis-
play updated results as of 26th April 2015 (Fig. 6). The persistence
probability of the epidemic in the potential study areas changed as
incidence in those areas decreased and the model was fitted to
more available data. There was a sharp decrease in persistence
probability for Port Loko, due to the decline in the epidemic occur-
ring there. In contrast, for Kambia and Western Area, the projec-
tions from February changed very little by April.
4. Discussion
This close collaboration between CMMID and Janssen R&D in
forecasting and planning a phase 3 Ebola vaccine trial had many
key benefits: firstly, the production of up-to-date epidemic projec-
tions gave better situational awareness to the clinical study team
and key decision makers at Janssen. These forecasts were based
on fitting a mechanistic transmission model to the current epi-
demiological data, thereby providing rigorous and realistic predic-
tions. Secondly, the mechanistic model provided a means by which
to assess the feasibility of the phase 3 effectiveness trial, and how
this changed through time. This is critical to trial planning, deter-
mining whether to proceed, and to understanding the effect of
logistical delays or constraints on feasibility. And thirdly, by fitting
mechanistic models to potential study regions individually, the
Fig. 2. Epidemic in Kambia, Port Loko, andWestern Area, Sierra Leone. Upper panels: Time points marked by dotted lines correspond with simulated trial start dates; 1st May
2015, 1st June 2015, and 1st of July 2015. Filled red circles are weekly EVD cases to which the model was fitted (blue line, with dark shaded region showing 50% credible
interval and light region showing 95% interval) and empty circles displays data after that date (not fitted). Grey areas show forward-simulations of possible epidemic
trajectories generated by the model, conditioned on extinction by 1 January 2016. Middle panels: Projections of the weekly number of reported cases rescaled to per 400,000
subjects. Horizontal dashed blue lines correspond to the static model incidence assumptions in [9], of 3, 5, 10, 20, and 40 reported cases per 400,000 person-months. Lower
panels: persistence probability in each area. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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forecasts provided a better understanding of the variability
between candidate sites and the impact that a trial might have
had on the epidemic. This allowed study team and decision makers
to assess the relative probability of trial success based on geo-
graphically specific information.
Other trials planned for Ebola vaccines in various parts of West
Africa faced challenges to feasibility as a result of the declining
incidence [5,12]. In this study, modelling was used to help gauge
the feasibility of the cluster-randomized design, by forecasting
incidence in potential regions, which was then used in power cal-
culations [9]. The dynamic transmission model could account for
both vaccine efficacy in those vaccinated as well as vaccine effec-
tiveness in the population. Trial simulations indicated how many
cases to expect in the vaccine and control arms for various trial
locations, start dates and hypotheses of vaccine efficacy and how
this changed over time. The trial simulations thus guided decisions
of trial location and feasibility. For example, the simulations indi-
cated that Kambia was more likely to have sustained transmission
compared to Western Area and Port Loko. Further, the rapid
decrease of the persistence probability over time urged the vaccine
development team at Janssen to explore alternative trial designs,
and, partly as a result of this work, it was decided to abandon
the effectiveness trial protocol as planned. Instead, a safety and
immunogenicity study was initiated in Kambia in October 2015.
The trial was intended to start during the declining phase of the
outbreak and the assumption on potential start dates reflects
realistic assumptions about operational timing. Additional work
could explore the feasibility of the trial starting at earlier points
of the outbreak. Importantly, this work was performed using
conservative estimates of vaccine efficacy after prime and boost
Fig. 3. Effect of start date on number of cases in vaccine and control arms, and persistence probability in each region, stratified by start date of the trial, for the baseline
scenario. Cumulative cases are only shown for trajectories that persist until that month. Where no boxplot is shown, all trajectories were extinct by that month.
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vaccination, which were used to calculate power of the effective-
ness trial. The effect of different assumptions of potential effect
of prime and boost vaccinations could be reassessed, also taking
into account durability of protection as suggested by recent
immunogenicity data in humans highlighting a strong and sus-
tained immune response [13]. Future work could also integrate for-
mal testing of vaccine efficacy [9] in the dynamic transmission
modelling framework, in a similar way as for an individually ran-
domized trial [5].
Although the model was able to accurately forecast the inci-
dence by district, a key limitation was that we could not model
cluster-level randomization due to insufficient data at this scale.
Also, although the model could suggest which was likely to be
the most favourable setting for the trial from an epidemiological
point of view, in reality, there may be logistical constraints such
as local customs, staff availability, manufacturing capacity and
storage, trials running in parallel, and other factors that would
affect trial feasibility. The scenarios that we explored were consid-
ered realistic at the start of the collaboration.
The model structure used here does not explicitly include dif-
ferent transmission mechanisms such as during unsafe burials
[14,15]. Instead, we used a flexible, stochastic, transmission rate
to capture the combined effect of these different transmission
components. The precise contribution of different factors was
likely to have changed over the course of the epidemic. For exam-
ple, by November 2014, trained burial teams and a safe burial com-
mand centre were established in Kambia and Port Loko (having
been previously established in Western Area) [16], so the risk of
Fig. 4. Distribution of total cases observed in each arm of the trial, stratified by start date, for the baseline scenario. Note that the color scale (which indicates the number of
simulations) is logarithmic. In simulations above the diagonal, more cases occurred in the vaccine arm. The p-values are from a one-sided Wilcoxon signed rank test for fewer
cases in the vaccine arm. There is one simulated point not shown, where the number of cases in the control arm is 100, and in the vaccine arm is 93, which occurred in Port
Loko.
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transmission due to unsafe practices was likely decreased by these
interventions. However, the model was able to capture overall pat-
terns of disease transmissions that occur as a result of changes in
transmission routes.
While the use of mechanistic transmission models in evaluating
vaccination programs is well established, their use in trial design,
planning, and analysis, is a relatively new and growing area of
research [17]. Designing interventions to reduce influenza trans-
mission gives different preferred trial designs whether the goal is
achieving power or taking account of economic constraints
[18,19]. Modelling has been used to propose new trials for HIV
antiviral treatment in serodiscordant couples [20], and has been
used specifically for vaccine trials for malaria [21,22], intestinal
helminths [23], wildlife vaccines [24], and nasopharyngeal bacteria
[25]. For Ebola vaccine trials, a semi-mechanistic model developed
during the epidemic addressed the feasibility of a proposed phase 3
trial in high risk individuals [12].
Our collaboration represents a novel example of close collabo-
ration between modellers and trial planners to guide the design
of a phase 3 trial during an epidemic. We delivered up-to-the-
minute projections for both the epidemic and trial feasibility from
academic researchers to industry partners. This type of information
is critical to trial planning and clinical development, and mathe-
matical models of disease transmission should be integrated into
trial design at the earliest possible stage.
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